AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$LEGN

Sanders Corazon (Corsee) D. sold $259K of LEGN

Sanders Corazon (Corsee) D. sold 27,370 shares of Legend Biotech Corp (LEGN) at $9.46 ($0.26M total) on 2026-09-29.

Original reporting
SEC EDGAR · Sanders Corazon (Corsee) D.
Published Oct 1, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LEGN
Bearish
medium confidence
Mentioned
$LEGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNBearishLow
01

Why it matters

The director's sale may be interpreted as a lack of confidence, but the amount is modest relative to the company's market cap.

02

Market read

Provides a fresh, albeit small, insider sell signal for Legend Biotech.

03

What to watch

Potential upcoming clinical data releases could offset the sell pressure.

Relevance 4/10Novelty 3/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$LEGNBearishMedium confidence
Context

Director Sanders Corazon sold 27,370 shares of Legend Biotech for $258,920 on Sep 29, 2026.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

A director sold a sizable block at $9.46 per share, indicating potential concerns; however the amount is relatively small for the market.

Market effects

Sector

Minimal impact on the biotech sector; typical insider sales are routine.

Regional

No significant regional effect.

Global

Limited to Legend Biotech investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Legend Biotech Corp

    Biotech firm listed on Nasdaq under ticker LEG N.

  • Individual
    Sanders Corazon D.

    Director of Legend Biotech who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LEGN insider trading history →

Related articles

OCT 2
$LEGNHighAI 8/10

Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

simplywall.st3 min
SEP 25
$LEGNMedAI 8/10

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

quiverquant.com2 min
AUG 25
$LEGNHighAI 8/10

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.

simplywall.st2 min
AUG 14
$LEGNMedAI 8/10

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.

aol.com6 min